Predictors of quality of life improvement in allergic rhinitis patients after sublingual immunotherapy

Annals of Otology, Rhinology and Laryngology

Volumn 124, Issue 6, 2015, Pages 430-436

  Katotomichelakis, Michael ^a   Riga, Maria ^a   Tripsianis, Gregory ^a   Balatsouras, Dimitrios ^a   Kourousis, Christos ^a   Danielides, Gerasimos ^a   Giotakis, Evangelos ^b   Danielides, Vassilios ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

Author keywords

allergic rhinitis; anosmia; asthma; immunotherapy; quality of life; sniffin' sticks

Indexed keywords

IMMUNOLOGIC AGENT; STALLERGEN; SUBLIVAC; UNCLASSIFIED DRUG; ALLERGEN;

ADULT; ALLERGIC RHINITIS; ARTICLE; ASSESSMENT OF HUMANS; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SHORT FORM 36; SMELLING; STATE TRAIT ANXIETY INVENTORY; SUBLINGUAL IMMUNOTHERAPY; TREATMENT DURATION; TREATMENT OUTCOME; ZUNG DEPRESSION SCALE; DOSE RESPONSE; FOLLOW UP; PROCEDURES; PSYCHOLOGY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINITIS, ALLERGIC; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; ADULT; ALLERGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RHINITIS, ALLERGIC; SUBLINGUAL IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 84940993710     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003489414565001     Document Type: Article

References (32)

1. Greiner AN, Hellings PW, Rotiroti G, Scadding GK,. Allergic rhinitis. Lancet. 2011; 378: 2112-2122.
2. Bhattacharyya N,. Functional limitations and workdays lost associated with chronic rhinosinusitis and allergic rhinitis. Am J Rhinol Allergy. 2012; 26: 120-122.
3. Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J,. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol. 2013; 160: 393-400.
4. Izquierdo-Domínguez A, Valero AL, Mullol J,. Comparative analysis of allergic rhinitis in children and adults. Curr Allergy Asthma Rep. 2013; 13: 142-151.
5. Baiardini I, Braido F, Tarantini F, et al. GA2LEN ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy. 2008; 63: 660-669.
6. Radulovic S, Calderon MA, Wilson D, Durham S,. Sublingual immunotherapy for all allergic rhinitis. Cochrane Database Syst Rev. 2010; 8 (12): CD002893.
7. Ciprandi G, Cadario G, Valle C, et al. Sublingual immunotherapy in polysensitized patients: effect on quality of life. J Investig Allergol Clin Immunol. 2010; 20: 274-279.
8. Wise SK, Woody J, Koepp S, Schlosser RJ,. Quality of life outcomes with sublingual immunotherapy. Am J Otolaryngol. 2009; 30: 305-311.
9. Walker SM, Durham SR, Till SJ, et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy. 2011; 41: 1177-1200.
10. Petalas K, Durham SR,. Allergen immunotherapy for allergic rhinitis. Rhinology. 2013; 51: 99-110.
11. Hankin CS, Cox L, Lang D, et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol. 2010; 104: 79-85.
12. Radulovic S, Wilson D, Calderon M, Durham S,. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011; 66: 740-752.
13. 2 LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010; 65: 1525-1530.
14. Welge-Luessen A, Hummel T, Stojan T, Wolfensberger M,. What is the correlation between ratings and measures of olfactory function in patients with olfactory loss? Am J Rhinol. 2005; 19: 567-571.
15. Hu B, Han D, Zhang L, et al. Olfactory event-related potential in patients with rhinosinusitis-induced olfactory dysfunction. Am J Rhinol Allergy. 2010; 24: 330-335.
16. Bousquet J, Anto JM, Demoly P, et al. Severe chronic allergic (and related) diseases: a uniform approach-a MeDALL-GA(2)LEN-ARIA position paper. Int Arch Allergy Immunol. 2012; 158: 216-231.
17. Dreborg S,. EAACI Subcommittee on Skin Tests. Skin tests used in type I allergy testing. Position paper. Allergy. 1989; 44 (suppl 10): S22-S31.
18. Hummel T, Kobal G, Gudziol H, Mackay-Sim A,. Normative data for the “Sniffin' Sticks� including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol. 2007; 264: 237-243.
19. Katotomichelakis M, Balatsouras D, Tripsianis G, Tsaroucha A, Homsioglou E, Danielides V,. Normative values of olfactory function testing using the “Sniffin' Sticks.�. Laryngoscope. 2007; 117: 114-120.
20. Simopoulos E, Katotomichelakis M, Gouveris H, Tripsianis G, Livaditis M, Danielides V,. Olfaction associated quality of life in chronic rhinosinusitis: adaptation and validation of an olfaction-specific questionnaire. Laryngoscope. 2012; 122: 1450-1454.
21. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J,. An inventory for measuring depression. Arch Gen Psych. 1961; 4: 53-63.
22. Fountoulakis KN, lacovides A, Samolis S, et al. Reliability, validity and psychometric properties of the Greek translation of the Zung Depression Rating Scale. BMC Psychiatry. 2001; 1-6.
23. Spielberger CD, Gorsuch RL, Lushene R, et al. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1983.
24. Ware JE,. The SF-36 Health Survey. In: Quality of Life and Pharmaeconomics in Clinical Trials, Spilker B, (ed. Philadelphia, PA: Lipincott-Raven; 1996: 337-346.
25. Pappa E, Kontodimopoulos N, Niakas D,. Validating and norming of the Greek SF-36 Health Survey. Qual Life Res. 2005; 14: 1433-1438.
26. Klimek L, Sperl A, van Twuijver E, et al. A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations. Clin Transl Allergy. 2014; 4: 23.
27. Norman GR, Sloan JA, Wyrwich KW,. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003; 41: 582-592.
28. Narkus A, Lehnigk U, Haefner D, Klinger R, Pfaar O, Worm M,. The placebo effect in allergen-specific immunotherapy trials. Clin Transl Allergy. 2013; 3: 42.
29. Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy. 2009; 64: 179-186.
30. Katotomichelakis M, Simopoulos E, Zhang N, et al. Olfactory dysfunction and asthma as risk factors for poor quality of life in upper airway diseases. Am J Rhinol Allergy. 2013; 27: 293-298.
31. Passalacqua G,. Specific immunotherapy in asthma: a synthetic review. J Asthma. 2013; 51: 29-33.
32. Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008; 38: 19-42.